Skin Cancer and Immunosuppression

Walder, B.; Robertson, M.R.; Jeremy, D.

doi:10.1016/s0140-6736(71)90602-7

Cited by 280 publications

(102 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the association between immunodeficiency and development of lymphoreticular tumors was well-established, Walder's report suggested that immunosuppressive treatment may also precipitate the development of SCC. 5 Subsequent studies confirmed the association between solid organ transplantation/immunosuppression and the development of SCC, BCC and other skin neoplasms. [6][7][8] The relative risk for such tumors in solid organ recipients is estimated to be 92 and 108 for women and men, respectively.…”

Section: Introductionmentioning

confidence: 86%

Skin cancer after nonmyeloablative hematopoietic cell transplantation

Cavalier

Shmalo

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 86%

Skin cancer after nonmyeloablative hematopoietic cell transplantation

Cavalier

Shmalo

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Skin cancers are the most common malignant conditions in transplant recipients and account for the substantial morbidity and mortality in such patients. Walder et al 1 , in 1971, were the first to identify this increased risk and publish their observations on a group of Australian renal-transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

Skin Cancer Incidence in Renal Transplant Recipients - A Single Center Study

Kalinová¹,

Májek²,

Stehlík³

et al. 2010

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims.To provide the first single-center study of a Czech renal transplant program that compares skin cancer risk estimates to the general population.Methods. We studied a total of 603 patients undergoing renal transplantation at the University Hospital Olomouc Transplant Center between January 1984 and December 2009. The mean time of follow-up was 5.5 years. Three patients were excluded for skin cancer diagnosis before transplant. The cohort was linked with the National Cancer Registry of the Czech Republic. For non-melanoma skin cancer (NMSC), the observed number of cancers were compared to the expected numbers of NMSC based on national cancer incidence rates stratified by age. The standartized incidence ratio (SIR) was calculated as observed-to-expected ratios.Results. We found a total of 127 cases of skin cancers in 55 patients. 52/55 (94.5%) were patients with non-melanoma skin cancers, 2/55 (3.6%) patients had malignant melanoma, and we uncovered one case of merkel cell carcinoma of the skin (1.8%). There were no cases of Kaposi's sarcoma, cutaneous lymphoma or malignant fibrous histiocytoma. For NMSC, the overall SIR was 7.39 (95% confidence interval 5.52-9.70). Thus, skin cancer was the most common malignant condition, representing 64.1% of all malignant tumours detected in study population.Conclusion. We confirmed that skin cancer is a major complication in renal transplant recipients. Therefore it is important to increase the intensity of surveillence for these lesions in transplant patients.

show abstract

“…The rise in skin cancer is attributed mostly to squamous cell carcinoma, which occurs up to 36 times as frequently as expected (20,22,23). A more rapid progression from premalignant lesions to squamous cell carcinoma is observed in immunosuppressed patients (19,24,25). Furthermore, this population is at risk for those skin cancers that recur multiple times and that appear at an earlier age than expected for the general population (19,20,24,26).…”

Section: Host Characteristicsmentioning

confidence: 90%

“…A more rapid progression from premalignant lesions to squamous cell carcinoma is observed in immunosuppressed patients (19,24,25). Furthermore, this population is at risk for those skin cancers that recur multiple times and that appear at an earlier age than expected for the general population (19,20,24,26). Evidence suggests that skin cancers in these patients are more aggressive and tend to metastasize more frequently than usual (19,25); therefore, more aggressive treatment and close follow-up are warranted.…”

Section: Host Characteristicsmentioning

confidence: 99%

Difficult Skin Cancers: Clinicopathologic Features and Management

Brown¹

1993

Baylor University Medical Center Proceedings

View full text Add to dashboard Cite

Skin Cancer and Immunosuppression

Cited by 280 publications

References 5 publications

Skin cancer after nonmyeloablative hematopoietic cell transplantation

Skin cancer after nonmyeloablative hematopoietic cell transplantation

Skin Cancer Incidence in Renal Transplant Recipients - A Single Center Study

Difficult Skin Cancers: Clinicopathologic Features and Management

Contact Info

Product

Resources

About